KR100208969B1 - Anti-ulcers drug containing extract from chap-rice - Google Patents
Anti-ulcers drug containing extract from chap-rice Download PDFInfo
- Publication number
- KR100208969B1 KR100208969B1 KR1019960047695A KR19960047695A KR100208969B1 KR 100208969 B1 KR100208969 B1 KR 100208969B1 KR 1019960047695 A KR1019960047695 A KR 1019960047695A KR 19960047695 A KR19960047695 A KR 19960047695A KR 100208969 B1 KR100208969 B1 KR 100208969B1
- Authority
- KR
- South Korea
- Prior art keywords
- glutinous rice
- rice extract
- ulcer
- extract
- ethanol
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 128
- 230000000767 anti-ulcer Effects 0.000 title abstract description 25
- 239000003814 drug Substances 0.000 title description 3
- 229940079593 drug Drugs 0.000 title description 3
- 241000209094 Oryza Species 0.000 claims abstract description 138
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 138
- 235000009566 rice Nutrition 0.000 claims abstract description 138
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 239000012153 distilled water Substances 0.000 claims abstract description 23
- 239000003699 antiulcer agent Substances 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 4
- 239000002244 precipitate Substances 0.000 claims description 20
- 230000000694 effects Effects 0.000 abstract description 38
- 231100000957 no side effect Toxicity 0.000 abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 70
- 208000007107 Stomach Ulcer Diseases 0.000 description 61
- 201000005917 gastric ulcer Diseases 0.000 description 59
- 241000700159 Rattus Species 0.000 description 34
- 238000002360 preparation method Methods 0.000 description 27
- 208000025865 Ulcer Diseases 0.000 description 21
- 231100000397 ulcer Toxicity 0.000 description 19
- 229940116901 diethyldithiocarbamate Drugs 0.000 description 17
- LMBWSYZSUOEYSN-UHFFFAOYSA-N diethyldithiocarbamic acid Chemical compound CCN(CC)C(S)=S LMBWSYZSUOEYSN-UHFFFAOYSA-N 0.000 description 17
- 230000035876 healing Effects 0.000 description 12
- 208000008469 Peptic Ulcer Diseases 0.000 description 7
- 230000037406 food intake Effects 0.000 description 7
- 208000011906 peptic ulcer disease Diseases 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 238000012869 ethanol precipitation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000001156 gastric mucosa Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229940095463 folic acid 0.5 mg Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000989 food dye Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명에 따르면, 찹쌀추출물을 유효성분으로 함유하는 항궤양제가 제공된다.According to the present invention, there is provided an anti-ulcer agent containing an extract of glutinous rice as an active ingredient.
본 발명에 사용되는 찹쌀추출물은 찹쌀 분말에 2-10배 무게의 증류수 가하여 추출한 찹쌀의 수(水)추출액 및 이 찹쌀추출액을 실온에서 12-24시간 방치한 후 원심분리하여 얻은 침전물인 찹살추출액침전분획이다.The glutinous rice extract used in the present invention is a glutinous rice extract obtained by adding distilled water having a weight of 2-10 times to glutinous rice powder and extracting the glutinous rice water and the glutinous rice extract at room temperature for 12-24 hours, Lt; / RTI >
본 발명의 찹쌀추출물은 부작용이 없고 항궤양효과가 뛰어나다.The glutinous rice extract of the present invention has no side effects and is excellent in anti-ulcer effect.
Description
제1도는 제조실시예 1의 찹쌀추출액이 흰쥐에서 에탄올에 의한 위궤양 유발을 방어하는 효과를 나타낸 흰쥐의 위 사진이다. 이 경우는 찹쌀추출액을 흰쥐에게 1회 경구 투여한 경우이다.FIG. 1 is a photograph of a rat showing the effect of the glutinous rice extract of Preparation Example 1 in preventing gastric ulcer induced by ethanol in rats. In this case, glutinous rice extract was orally administered to rats once.
제2도는 제조실시예 1의 찹쌀추출액이 흰쥐에서 에탄올에 의한 위궤양 유발을 방어하는 효과를 나타낸 그래프이다. 이 경우는 찹쌀추출액을 흰쥐에게 1회 경구 투여한 경우이다.FIG. 2 is a graph showing the effect of the glutinous rice extract of Preparation Example 1 in preventing gastric ulcer induced by ethanol in rats. In this case, glutinous rice extract was orally administered to rats once.
제3도는 제조실시예 1의 찹쌀추출액이 흰쥐에서 에탄올에 의한 위궤양 유발을 방어하는 효과를 나타내는 흰쥐의 위 사진이다. 이 경우는 찹쌀추출액을 흰쥐에게 3일 섭취하게 한 경우이다.FIG. 3 is a photograph of the rat showing the effect of preventing the gastric ulcer induced by ethanol from the glutinous rice extract of Preparation Example 1 in rats. In this case, the glutinous rice extract was given to the rats for 3 days.
제4도는 제조실시예 1의 찹쌀추출액이 흰쥐에서 에탄올에 의한 위궤양 유발을 방어하는 효과를 나타내는 그래프이다. 이 경우는 찹쌀추출액을 흰쥐에게 3일 섭취하게 한 경우이다.FIG. 4 is a graph showing the effect of the glutinous rice extract of Preparation Example 1 on the prevention of gastric ulcer induced by ethanol in rats. In this case, the glutinous rice extract was given to the rats for 3 days.
제5도는 제조실시예 1의 찹쌀추출액이 그 농도에 따라 흰쥐에서 에탄올에 의한 위궤양 유발을 방어하는 효과를 나타내는 그래프이다. 이 경우는 찹쌀추출액을 흰쥐에게 3일 섭취하게 한 경우이다.FIG. 5 is a graph showing the effect of the glutinous rice extract of Preparation Example 1 against the induction of gastric ulcer by ethanol in rats according to the concentration thereof. In this case, the glutinous rice extract was given to the rats for 3 days.
제6도는 제조실시예의 1의 찹쌀추출액이 흰쥐에서 에탄올 유발 위궤양을 치유하는 효과를 나타내는 그래프이다.FIG. 6 is a graph showing the effect of the glutinous rice extract of Preparation Example 1 on healing ethanol-induced gastric ulcer in rats.
제7도는 제조실시예 1의 찹쌀추출액이 흰쥐에서 DDC 유발 위궤양을 방어하는 효과를 나타내는 흰쥐의 위 사진이다.FIG. 7 is a photograph of the rat showing the effect of the glutinous rice extract of Preparation Example 1 in protecting the DDC-induced gastric ulcer in rats.
제8도는 제조실시예 1의 찹쌀추출액이 흰쥐에서 DDC 유발 위궤양을 방어하는 효과를 나타내는 그래프이다.FIG. 8 is a graph showing the effect of the glutinous rice extract of Preparation Example 1 in protecting the DDC-induced gastric ulcer in rats.
제9도는 제조실시예 1의 찹쌀추출액을 십이지장궤양 환자가 섭취하기전과 후의 내시경 사진이다.FIG. 9 is an endoscopic photograph taken before and after the ingestion of the glutinous rice extract of Preparation Example 1 by a duodenal ulcer patient. FIG.
제10도는 제조실시예 2의 찹쌀추출액침전분획이 그 양에 따라 흰쥐에서 에탄올에 의한 위궤양 유발을 방어하는 효과를 나타내는 그래프이다.FIG. 10 is a graph showing the effect of the precipitated fraction of the glutinous rice extract in Preparation Example 2 against the induction of gastric ulceration by ethanol in rats according to the amount thereof.
제11도는 제조실시예 2의 찹쌀추출액침전분획이 흰쥐에서 에탄올 유발 위궤양을 치유하는 효과를 나타내는 그래프이다.FIG. 11 is a graph showing the effect of the glutinous rice extract-precipitated fraction of Preparation Example 2 on healing ethanol-induced gastric ulcer in rats.
제12도는 제조실시예 2의 찹쌀추출액침전분획이 흰쥐에서 DDC 유발 위궤양을 방어하는 효과를 나타내는 그래프이다.FIG. 12 is a graph showing the effect of the glutinous rice extract-precipitated fraction of Preparation Example 2 in protecting the DDC-induced gastric ulcer in rats.
본 발명은 찹쌀추출물을 유효성분으로 함유하는 항궤양제에 관한 것으로, 구체적으로는 찹쌀의 수(水)추출액 도는 수추출액의 침전분획을 유효성분으로 함유하는 부작용이 없고 항궤양 효과가 뛰어난 항궤양제에 관한 것이다.The present invention relates to an anti-ulcer agent containing an extract of glutinous rice as an active ingredient. More specifically, the present invention relates to an anti-ulcer agent comprising a water extract of glutinous rice or a precipitated fraction of a water extract as an active ingredient, .
소화성궤양에 대한 약물치료의 주 목적은 통증을 해소하고 궤양자체를 치유하는 데 있으며, 부수적으로는 궤양재발과 합병증을 예방하는 데 있다. 이를 위해 현재 통용되는 항궤양제로는 항산제, H2-수용체 길항제, 항콜린성 약물 등이 있으나 이들 약제의 대부분이 다양한 부작용을 나타내기 때문에 장기 복용시 주의를 요하고 있다.The main purpose of pharmacotherapy for peptic ulcer is to relieve pain and heal the ulcer itself, and incidentally to prevent ulcer recurrence and complications. Anticoagulants, H 2 -receptor antagonists, and anticholinergic drugs are commonly used as antiulcer agents. However, since most of these drugs exhibit various side effects, attention should be paid to long-term use.
한편, 찹쌀은 일부지역에서 민간요법으로 소화성궤양 환자들이 복용하여 왔으나 과학적 근거가 분면하지 않고 이에 대한 구체적 자료가 문헌상 보고된 예는 없다.On the other hand, glutinous rice has been consumed by peptic ulcer patients in some areas by folk remedies, but the scientific basis is not divided and there is no specific data reported in the literature.
이어 본 발명자들은 현재 상용되고 있는 천연식품으로서 생체에 대한 안정성이 매우 높은 찹쌀로부터 부작용이 없고 항궤양 효과가 뛰어난 항궤양제의 개발에 대하여 연구를 하였다.The inventors of the present invention have studied the development of an anti-ulcer agent which has no side effects from glutinous rice, which is highly stable to living organisms, and has excellent anti-ulcer effect.
본 발명자들은 천연식품인 찹쌀의 분말로부터 수(水)추출액 (이하 찹쌀추출액이라 함) 또는 이 찹쌀추출액으로부터 침전분획 (이하 찹쌀추출액침전분획 이라 함)을 만들어 찹쌀추출물로 하고, 이들을 사용하여 동물실험과 임상실험을 시행한 결과, 이들 찹쌀추출물이 궤양 발생을 방어하며 발생된 궤양을 치유하는데 탁월한 효과가 있음을 발견하여 본 발명을 완성하였다.The present inventors made a glutinous rice extract (hereinafter referred to as "glutinous rice extract") or a precipitate fraction (hereinafter referred to as "glutinous rice extract precipitate fraction") from a glutinous rice extract as a natural food, And found that these glutinous rice extracts have an excellent effect for preventing ulcers from occurring and for healing ulcers that have occurred, thus completing the present invention.
본 발명의 목적은 찹쌀추출물을 함유하는 부작용이 없고 항궤양효과가 뛰어난 항궤양제를 제공하는 데 있다.It is an object of the present invention to provide an anti-ulcer agent which has no side effects containing glutinous rice extract and has excellent anti-ulcer effect.
본 발명에 사용되는 찹쌀추출물은 2가지 형태로 사용할 수 있는데, 찹쌀 분말에 2-10배 무게의 증류수를 가하여 진탕한 후 혼합액을 원심분리하여 얻은 상층액을 사용하거나, 이 찹쌀추출액을 실온에서 12-24시간 방치한 후 원심 분리하여 얻은 침전물을 사용할 수 있다. 이때 증류수 대신에 수돗물, 생수 같은 음용수를 사용할 수도 있다.The glutinous rice extract used in the present invention can be used in two forms. The glutinous rice powder is shaken by adding distilled water having a weight of 2-10 times to the glutinous rice powder, and then the supernatant obtained by centrifuging the mixture is used. -24 hours and then centrifuged to obtain a precipitate. Drinking water such as tap water or bottled water may be used instead of distilled water.
본 발명의 항궤양제에서 찹쌀추출물의 1회 투여량은 그 사용상태에 따라 찹쌀 20-30g의 추출액 또는 찹쌀 50-100gdml 추출액침전분획이다. 찹쌀추출액침 전분획은 비록 찹쌀추출액의 항궤양 활성(活性)의 40-50만을 지니고 있으나, 찹쌀추출물로 추출액침전분획을 사용할 경우 이와 동일한 항궤양 활성을 가지는 찹쌀추출액을 사용할 때보다 사용되는 찹쌀추출물의 그 무게와 용량이 현저히 줄어지므로(10이내), 실제 항궤양제를 제조할 때 제제중에 함유하는 찹쌀추출물의 양과 제제의 용량을 보다 쉽게 조절할 수 있게 하는 장점을 가진다.In the anti-ulcer agent of the present invention, a single dose of the glutinous rice extract is an extract of glutinous rice of 20-30 g or a precipitate fraction of 50-100 g of glutinous rice extract. Although the glutinous rice extract precipitate fraction has an anti-ulcer activity (activity) of 40-50 However, the weight and the volume of the glutinous rice extract, which is used more than the glutinous rice extract having the same anti-ulcer activity, are remarkably reduced when the extract precipitate fraction is used as the glutinous rice extract (10 ), It has an advantage that the amount of the glutinous rice extract contained in the preparation and the dosage of the preparation can be more easily controlled when the actual anti-ulcer agent is manufactured.
본 발명에서 찹쌀추출물을 함유하는 항궤양제는 액제, 정제, 캡슐제와 같은 경구 투여형태이다. 바람직한 경구 투여형태는 액제, 정제, 캡슐제이며, 이는 젤라틴, 솔비톨, 트라가칸트, 폴리비닐피롤리돈 등의 결합제 ; 유당, 설탕, 옥수수 전분, 글리신 등의 충전제 ; 폴리에틸렌글리콜, 실리카 등의 윤활제 ; 전분등의 붕해제 ; 습윤제를 포함하는 통상적인 부형제를 함유할 수 있다.In the present invention, the anti-ulcer agent containing the glutinous rice extract is an oral dosage form such as a liquid, a tablet or a capsule. Preferred oral dosage forms are liquids, tablets, capsules, including binders such as gelatin, sorbitol, tragacanth, and polyvinylpyrrolidone; Fillers such as lactose, sugar, corn starch, glycine and the like; Lubricants such as polyethylene glycol and silica; Disintegrating such as starch; And may contain conventional excipients including wetting agents.
정제는 위장관내에서의 분해 및 흡수를 조절하기 위해 통상적으로 사용되는 약제학적 첨가제, 예를 들면 설탕, 셀룰로오스 또는 그 유도체, 폴리비닐피롤리돈, 식품염료, 염색락카, 방향족화제 및 안료 등과 같은 보호제, 향미제 및/또는 착색제를 이용하여 당의정으로 전환시킬 수 있다.Tablets may also contain pharmaceutically acceptable additives commonly used to control the degradation and absorption in the gastrointestinal tract, such as sugars, cellulose or derivatives thereof, polyvinyl pyrrolidone, food dyes, dyeing lacquers, aromatizing agents and pigments, , A flavoring agent and / or a coloring agent.
본 발명의 첩쌀추출물은 실험동물 흰쥐에게 인위적으로 유발시킨 궤양을 방어 또는 치유하는 항궤양 효과가 탁월한 것으로 나타났는데, 이를 찹쌀추출물의 사용상태에 따라 찹쌀추출액을 사용한 경우와 찹쌀추출액침전분획을 사용한 경우로 나누어 설명하면 하기와 같다.The rice extract of the present invention has excellent anti-ulcer effect to protect or heal an artificially induced ulcer in experimental animal rats. The use of glutinous rice extract and glutinous rice extract precipitate fraction according to the use condition of glutinous rice extract The following will be described.
즉, 흰쥐에게 찹쌀추출액을 1회 경구투여한 후 에탄올을 투여하여 위궤양을 일으킨 경우 [평균 위궤양 지수 (위궤양 면적/위점막 전체 면적 x 100) 6.1]는 증류수 투여후 에탄올을 투여하여 위궤양을 일으킨 대조군의 경우 (평균 위궤양 지수 74.2)보다 위궤양 유발이 적어, 찹쌀추출액이 위궤양을 방어하는 항궤양 효과가 큰 것으로 나타났다.That is, when rats were orally administered glutinous rice extract once and then administered with ethanol to cause gastric ulcer [average gastric ulcer index (area of gastric ulcer / area of gastric mucosa x 100) 6.1 ] Was significantly higher in the control group treated with ethanol after distilled water administration and in the gastric ulcer group (mean gastric ulcer index 74.2 ), And the anti-ulcer effect of glutinous rice extract to protect against gastric ulcer was high.
흰쥐에게 찹쌀추출액을 3 일 동안 자유로이 섭취할 수 있도록 한 뒤 에탄올을 투여하여 위궤양을 유발한 경우에도, 상기의 결과와 일치하였다.The results were consistent with the above results when rats were allowed to consume glutinous rice extract for 3 days and then administered with ethanol to induce gastric ulcer.
찹쌀추출물의 농도에 따른 효과를 보기위하여, 흰쥐에게 농도를 달리하여 찹쌀추출액을 3일 동안 섭취하게 한 뒤 에탄올을 투여하여 위궤양을 일으킨 결과, 찹쌀추출액의 농도가 증가함에 따라 그 항궤양 효과가 점차 큰 것으로 나타났다.In order to examine the effect of glutinous rice extract on the concentration of glutinous rice extract, glutinous rice extract was administered to the rats at different concentrations for 3 days and ethanol was administered to cause gastric ulcer. As the concentration of glutinous rice extract increased, Respectively.
한편, 에탄올을 경구 투여하여 위궤양을 발생시킨 다음 찹쌀추출액을 섭취하게 한 경우는 에탄올 투여후 증류수를 섭취하게 한 경우보다 위궤양 치유속도가 현저히 빠른 것으로 나타나, 찹쌀추출액이 흰쥐에서 에탄올에 의한 위궤양을 치유하는 항궤양 효과가 큰 것으로 나타났다.On the other hand, when the ethanol was orally administered to cause gastric ulcer and then ingested the glutinous rice extract, the gastric ulcer healing rate was significantly faster than that of the ethanol-administered distilled water, and the glutinous rice extract was found to heal the gastric ulcer caused by ethanol in the rat The anti-ulcer effect was greater.
흰쥐에게 찹쌀추출액을 3일 동안 섭취하도록 하고 디에틸디티오카바메이트(Diethyldithiocarbamate, DDC)를 피하주사하여 위궤양을 유발한 경우 (평균 위궤양 지수 1.3)에도 증류수 섭취후 DDC 주사하여 위궤양을 유발한 대조군의 경우 (평균 위궤양지수 12.2)보다 위궤양 유발이 적어, 찹쌀추출액이 DDC 유발 위궤양도 방어하는 항궤양 효과가 큰 것으로 나타났다.Rats were fed glutinous rice extract for 3 days and subcutaneously injected with diethyldithiocarbamate (DDC) to induce gastric ulcer (mean gastric ulcer index 1.3 ) And DDC after ingestion of distilled water resulted in gastric ulcer in the control group (mean gastric ulcer index 12.2 ), And the anti - ulcer effect of glutinous rice extract was also stronger in DDC - induced gastric ulcer.
소화성 궤양 환자에게 찹쌀추출액을 1일 3회 (찹쌀의 10배 증류수 추출액을 1회당 250ml)씩 2-6주 동안 섭취하게 한 결과, 환자들이 호소하던 상복 부통증이 소멸되었고 이 중 1인을 대상으로 내시경으로 관찰한 결과 찹쌀추출액 섭취 4주 후에 십이지장 궤양이 거의 치유되었고 11주 후에는 치유흔적만이 관찰되어, 찹쌀추출액이 사람의 소화성 궤양을 치유하는 항궤양 효과가 큰 것으로 나타났다.In patients with peptic ulcer, the glutinous rice extracts were taken three times a day (250 ml per 1 cup of distilled water extract of glutinous rice) for 2-6 weeks, resulting in the disappearance of the abdominal pain complained by the patients and one of them Endoscopic examination showed that the duodenal ulcer was almost healed after 4 weeks of ingestion of the glutinous rice extract and only the healing trace was observed after 11 weeks. The glutinous rice extract showed a high anti - ulcer effect, which heals human peptic ulcer.
한편, 찹쌀추출액침전분획이 에탄올에 의한 위궤양을 방어하는 효과를 규명하기 위하여, 흰쥐에게 양을 달리하여 찹쌀추출액침전분획을 경구투여한 결과, 찹쌀추출액침전분획의 양이 증가함에 따라 그 항궤양 효과가 점차 증가하는 것으로 나타났다.On the other hand, in order to investigate the effect of the ethanol precipitation fraction of glutinous rice extract on the inhibition of gastric ulcer, the amount of glutinous rice extract solution precipitated fraction was increased and the anti - ulcer effect Of the total population.
또한 에탄올을 경구 투여하여 위궤양을 발생시킨 다음 찹쌀추출액침전분획을 섭취하게 한 경우는 에탄올을 투여하여 위궤양을 유발한 후 증류수를 섭취하게 한 경우보다 위궤양 치유속도가 현저히 빠른 것으로 나타나, 찹쌀추출액침전분획이 에탄올에 의한 위궤양을 치유하는 항궤양 효과가 큰 것으로 나타났다.In addition, when the ethanol was administered orally to the stomach, the stomach ulcer healing rate was significantly faster than when the stomach ulcer was ingested and the ingestion of the glutinous rice extract precipitate fraction. The anti-ulcer effect that heals the stomach ulcer caused by ethanol is large.
흰쥐에게 찹쌀추출액침전분획을 섭취하게 한 후 DDC를 피하주사하여 위궤양을 유발한 경우 (평균 위궤양 지수 1.6)는 증류수를 섭취하게 한 후 DDC를 피하주사하여 위궤양을 유발한 대조군의 경우 (평균 위궤양 지수 12.6)보다 위궤양을 적게 유발하여, 찹쌀추출액침전분획이 DDC에 의한 위궤양을 방어하는 항궤양 효과가 큰 것으로 나타났다.When DDC was injected subcutaneously in rats after ingesting the glutinous rice extract precipitate fraction, the gastric ulcer was induced (average gastric ulcer index 1.6 ) Were fed with distilled water and subcutaneously injected with DDC to induce gastric ulcer in the control group (mean gastric ulcer index 12.6 ), And the anti-ulcer effect of the glutinous rice extract precipitate fraction was shown to be superior to DDC to prevent gastric ulcer.
본 발명의 찹쌀추출액 또는 찹쌀추출액침전분획은 부작용이 없으며 매우 안전하다. 즉, 본 발명의 찹쌀추출액을 흰쥐에게 3일 동안 자유로이 섭취시키거나, 소화성궤양 환자에게 찹쌀추출액을 250ml 씩 1일 3회, 2-11 주간 복용시키더라도 찹쌀추출액의 부작용은 전혀 관찰되지 않았으며, 또한 본 발명의 찹쌀추출액침전분획을 흰쥐에게 3일 동안 자유로이 섭취시키거나 정상인 지원자 5인에게 5g씩 1일 3회, 10주간 복용시키더라도 찹쌀추출액침전분획의 부작용은 전혀 관찰되지 않았다.The glutinous rice extract or the glutinous rice extract precipitate fraction of the present invention has no side effects and is very safe. That is, even when the glutinous rice extract of the present invention was ingested for 3 days in rats or when 250 ml of glutinous rice extract was administered to a patient suffering from peptic ulcer 3 times a day for 2-11 weeks, no adverse effect of the glutinous rice extract was observed at all, Also, no side effect of the glutinous rice extract precipitate fraction was observed when the glutinous rice extract precipitate fraction of the present invention was freely taken for 3 days in rats or 5 g for 5 healthy volunteers 3 times a day for 10 weeks.
이하 본 발명을 실시예 및 실험예에 의하여 더욱 상세히 설명하나, 본 발명이 이에 의하여 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples, but the present invention is not limited thereto.
[제조실시예 1][Manufacturing Example 1]
(찹쌀추출액의 제조)(Preparation of glutinous rice extract)
본 발명에서 사용한 찹쌀분말은 찹쌀은 몰타르(mortar)로 분쇄하거나 찹쌀분말을 구입한 것이다.The glutinous rice powder used in the present invention is obtained by grinding glutinous rice with a mortar or purchasing glutinous rice powder.
찹쌀 분말에 10배 무게의 증류수를 가하고 믹서(mixer)기를 사용하여 30초간 3회 진탕하였다. 진탕 후 혼합액을 5,000×g에서 10분간 원심분리하여 상층액을 얻어 찹쌀추출액으로 하였다.Distilled water having a weight of 10 times was added to the glutinous rice powder and shaken three times for 30 seconds using a mixer. After shaking, the mixture was centrifuged at 5,000 × g for 10 minutes to obtain supernatant, which was used as a glutinous rice extract.
[제조실시예 2][Manufacturing Example 2]
(찹쌀추출액침전분획의 제조)(Preparation of a glutinous rice extract precipitate fraction)
상기 제조실시예 1에서 제조한 찹쌀추출액을 실온에 12-24 시간 방치한 후 5,000×g에서 10분간 원심분리하여 침전물을 얻어 찹쌀추출액침전분획으로 하였다.The glutinous rice extract prepared in Preparation Example 1 was allowed to stand at room temperature for 12-24 hours, and then centrifuged at 5,000 × g for 10 minutes to obtain a precipitate, which was used as a glutinous rice extract precipitate fraction.
[실험예 1][Experimental Example 1]
(동물 위궤양 모델에서 찹쌀추출액의 항궤양작용 확인)(Anti-ulcerative effect of glutinous rice extract in animal gastric ulcer model)
본 발명에서 사용한 위궤양 유발과 궤양지수의 측정방법은 다음과 같다.The method of measuring gastric ulcer induction and ulcer index used in the present invention is as follows.
체중 250g 내외의 흰쥐 (Sprague-Dawley)에게 에탄올 1ml를 경구투여하거나, DDC (diethyldithiocarbamate)를 체중 1kg 당 800mg 씩 피하주사하여 위궤양을 유발시켰다.Sprague-Dawley rats weighing 250 g were orally administered 1 ml of ethanol, or DDC (diethyldithiocarbamate) was injected subcutaneously 800 mg per 1 kg of body weight to induce gastric ulcer.
에탄올 투여 후 1.5 시간, DDC 투여 후 12 시간에 개복하여 위를 절취하고 대만곡을 따라 절개한 다음 사진을 찍고, 화상분석기 (image analyzer, 독일 kontron社 model IBAS 2000)를 이용하여 궤양부위의 면적을 측정하였다. 측정한 결과는 궤양지수로 표시하였는데 이는 위점막의 전체 면적에 대한 궤양부위 면적의 백분율이다.Ethanol for 1.5 hours and DDC for 12 hours. The stomach was dissected and incised along the Taiwanese tongue. The photograph was taken and the area of the ulcer area was measured using an image analyzer (model IBAS 2000, Germany) Respectively. The results were expressed as ulcer index, which is the percentage of the area of the ulcer area relative to the total area of the gastric mucosa.
측정된 결과에 대한 통계학적 유의성 검증은 Student's t-test에 의하였다.Statistical significance was checked by Student's t-test.
1) 에탄올 유발 위궤양에 대한 찹쌀추출액의 항궤양작용 확인1) Identification of anti-ulcer activity of glutinous rice extract against ethanol-induced gastric ulcer
① 찹쌀추출액을 1회 경구 투여한 경우 찹쌀추출액의 에탄올에 의한 궤양에 대한 방어 효과① Protective effect of glutinous rice extract on the ulcer caused by ethanol when the glutinous rice extract was orally administered once
제조실시예 1의 찹쌀추출액 또는 증류수를 흰쥐에 1ml 씩 경구 투여하고 30분 후에 에탄올 1ml를 경구 투여하여 위궤양 발생 정도를 측정 비교하였다. 각 실험군의 흰쥐의 수는 10마리였다.1 ml of the glutinous rice extract or distilled water of Preparation Example 1 was orally administered to each rat in an amount of 1 ml, and 30 minutes later, 1 ml of ethanol was orally administered to compare the degree of gastric ulcer formation. The number of rats in each experimental group was 10.
제1도는 각 실험군의 대표적인 사진이며, 제2도는 이 실험을 종합한 결과이다. 제2도에서 볼 수 있듯이 증류수를 투여한 대조군의 궤양지수는 평균 74.2인데 비해 찹쌀추출액 투여군의 궤양지수는 평균 6.1로서 찹쌀추출액은 에탄올에 위한 위궤양을 크게 방어하였다.Figure 1 is a representative photograph of each experimental group, and Figure 2 is the result of synthesizing these experiments. As shown in Figure 2, the ulcer index of the control group treated with distilled water averaged 74.2 While the ulcer index of the group treated with glutinous rice extract was 6.1 As a result, glutinous rice extract significantly inhibited gastric ulcer for ethanol.
② 찹쌀추출액을 3일 섭취시킨 경우 찹쌀추출액의 에탄올에 의한 위궤양에 대한 방어 효과② Protection effect of glutinous rice extract on gastric ulcer caused by ethanol ingestion of glutinous rice extract for 3 days
제조실시예 1의 찹쌀추출액 또는 증류수를 물통에 넣어 3일 동안 자유롭게 마실 수 있도록 한 뒤 에탄올을 투여하고 위궤양 발생정도를 측정 비교하였다. 그 결과 제3도와 제4도에서 볼 수 있듯이 찹쌀추출액은 에탄올 유발 위궤양을 크게 방어하였으며, 이는 전술한 제1도와 제2도의 결과와 비슷한 결과이다.The glutinous rice extract or distilled water of Preparation Example 1 was placed in a water bottle for 3 days to be freely drinkable. Ethanol was administered and the degree of gastric ulcer was measured and compared. As a result, as shown in FIGS. 3 and 4, the glutinous rice extract significantly inhibited the ethanol-induced gastric ulcer, which is similar to the result of the above-mentioned first and second figures.
③ 찹쌀추출액의 농도에 따른 항궤양 효과③ Anti-ulcer effect according to concentration of glutinous rice extract
제조실시예 1의 찹쌀추출액에 증류수를 가하여 1-10배 희석한 다음 각 희석액을 동물이 3일 동안 섭취하도록 하고 에탄올을 투여하여, 위궤양 발생정도를 측정 비교하였다.Distilled water was added to the glutinous rice extract of Preparation Example 1 to dilute 1 to 10 times. Each dilution was administered to the animals for 3 days, and ethanol was administered to measure and compare the incidence of gastric ulcers.
그 결과 제5도에 나타낸 바와 같이 10배 희석액의 항궤양작용은 미미하였으나 찹쌀추출액의 농도가 증가함에 따라 그 항궤양작용이 점차 강해짐을 알 수 있다.As a result, as shown in FIG. 5, the anti-ulcer action of the 10-fold dilution was insignificant, but the anti-ulcer action of the 10-fold dilution was gradually increased as the concentration of the glutinous rice extract was increased.
④ 에탄올에 의한 위궤양에 대한 찹쌀추출액의 치유 효과④ Healing effect of glutinous rice extract on gastric ulcer caused by ethanol
에탄올 유발 위궤양에 대한 찹쌀추출액의 치유효과를 보기 위해 에탄올을 경구 투여하여 위궤양을 발생시킨 다음 에탄올 투여 1.5시간 후부터 물통에 제조실시예 1의 찹쌀추출액 또는 증류수를 담아 섭취하도록 하고, 24 시간 간격으로 도살하여 위궤양지수를 측정하였다.In order to examine the healing effect of the glutinous rice extract against the ethanol-induced gastric ulcer, ethanol was orally administered to induce gastric ulcer. After 1.5 hours of ethanol administration, the glutinous rice extract or distilled water of Preparation Example 1 was taken in a bucket, The gastric ulcer index was measured.
그 결과 제6도에 나타 낸 바와 같이 찹쌀추출액 섭취 군은 증류수 섭취 대조군에 비하여 위궤양 치유 속도가 현저히 빨랐다.As a result, as shown in Fig. 6, the rate of gastric ulcer healing was significantly faster than that of the control group.
이상의 실험결과들을 종합해 볼 때 찹쌀추출액은 에탄올 유발 위궤양에 대하여 예방은 물론 치료 효과를 다 같이 나타냄을 알 수 있다.Based on the above results, it can be seen that the glutinous rice extract shows the preventive effect as well as the therapeutic effect against the ethanol induced gastric ulcer.
2) DDC 유발 위궤양에 대한 찹쌀추출액의 항궤양작용 확인2) Identification of anti-ulcer activity of glutinous rice extract against DDC-induced gastric ulcer
제조실시예 1의 찹쌀추출액 또는 증류수를 물통에 담아 동물들이 3일 동안 섭취하도록 한 뒤 DDC를 체중 1kg 당 800mg 씩 피하 주사하고 12시간 후에 도살하여 위궤양지수를 측정하였다.The glutinous rice extract or distilled water of Preparation Example 1 was placed in a bucket and the animals were allowed to ingest for 3 days. The DDC was subcutaneously injected at 800 mg per 1 kg of body weight and slaughtered after 12 hours to measure the gastric ulcer index.
제7도는 각 실험군의 대표적인 사진이며, 제8도는 이 실험을 종합한 결과이다. 제8도에서 볼 수 있듯이 찹쌀추출액 섭취군의 평균 궤양지수는 1.3로서 증류수 섭취 대조군의 평균 궤양지수 12.2에 비해 현저히 낮았다.FIG. 7 is a representative photograph of each experimental group, and FIG. 8 is the result of synthesizing these experiments. As shown in Fig. 8, the average ulcer index of the glutinous rice extract group was 1.3 The average ulcer index of the control group was 12.2 Respectively.
[실험예 2][Experimental Example 2]
(소화성궤양 환자에서 찹쌀추출액의 항궤양작용 확인)(Confirming the Anti-Ulcer Activity of Glutinous Rice Extract in Patients with Peptic Ulcer)
상복부통증을 주 증상으로 호소하며 소화성궤양으로 진단된 8명의 지원자를 대상으로 제조실시예 1의 찹쌀추출액을 제공하여 섭취하도록 하였다. 실험기간 중 환자들은 찹쌀추출액 250ml 씩을 아침, 점심, 저녁, 하루 3회 마시도록 하고 다른 항궤양 치료제를 복용하지 않도록 하였으며, 일주일 간격으로 진찰하여 통증의 진행상태를 관찰하였다.Eight applicants diagnosed with peptic ulcer complained of upper abdominal pain as a main symptom were provided with the glutinous rice extract of Preparation Example 1 to be ingested. During the study period, patients were asked to drink 250 ml of glutinous rice extract every morning, lunch, dinner, 3 times a day, and not to take other antiulcer drugs.
그 결과 표 1 에 나타난 바와 같이 조사한 환자 8명 모두에게 2-6주간의 찹쌀추출액 섭취로 호소하던 상복부통증이 소멸되었다.As a result, as shown in Table 1, all 8 patients who had been treated with glutinous rice extract ingested for 2-6 weeks were abolished from upper abdominal pain.
제9도는 이상의 환자들 중 1인을 대상으로 내시경을 통해 궤양의 진행상태를 관찰한 사진이다. 이 환자는 찹쌀추출액 섭취 전 십이지정에 직경 1.5×2.0cm 크기의 타원형 궤양을 가지고 있었으나 찹살추출액 섭취 4주 후에는 궤양이 거의 치유되었고 11주 후에는 치유 흔적만을 나타내었다.Fig. 9 is a photograph of the progress of ulceration through endoscopy in one of the above patients. The patient had elliptical ulcers of 1.5 × 2.0 cm in diameter at the 12th designation before the ingestion of glutinous rice extract, but the ulcer was almost healed after 4 weeks of ingestion of Chipsuck extract and only showed signs of healing after 11 weeks.
[실험예 3][Experimental Example 3]
(동물 위궤양 모델에서 찹쌀추출액침전분획의 항궤양작용 확인)(Confirming the Anti-Ulcer Activity of the Particles of the Extract of Glutinous Rice Extract in the Animal Stomach Model)
1) 에탄올 유발 위궤양에 대한 찹쌀추출액침전분획의 항궤양작용 확인1) Confirming the anti-ulcer activity of the precipitated fraction of glutinous rice extract on ethanol-induced gastric ulcer
①찹쌀추출액침전분획의 에탄올에 의한 궤양에 대한 방어 효과① Protective effect of ethanol precipitation fraction of glutinous rice extract on ulcer
제조실시예 2의 찹쌀추출액침전분획을 양 (0-25 mg)을 달리하여 1ml 증류수에 부유시켜 이를 흰쥐에 경구 투여하고 30분 후에 에탄올 1ml를 경구 투여하여 위궤양 발생 정도를 측정 비교하였다.The glutinous rice extract precipitate fraction prepared in Example 2 was suspended in 1 ml of distilled water in different amounts (0-25 mg), orally administered to rats, and 1 ml of ethanol was orally administered 30 minutes later.
그 결과 제10도에 나타낸 바와 같이 1mg/ml 부유액의 항궤양작용은 미미하였으나 찹쌀추출액침전분획의 양이 증가함에 따라 궤양방어효과가 점차 강해짐을 알 수 있다.As a result, as shown in FIG. 10, the anti-ulcer effect of the 1 mg / ml suspension was insignificant, but the effect of the ulcer defense was gradually enhanced as the amount of the precipitate fraction of the glutinous rice extract was increased.
② 찹쌀추출액침전분획의 에탄올에 의한 궤양에 대한 치유 효과② Healing effect of ethanol precipitation fraction of glutinous rice extract on ulcer
에탄올을 경구 투여하여 위궤양을 발생시킨 다음 에탄올 투여 1.5시간 후부터 물통에 제조실시예 2의 찹쌀추출액침전분획 부유액 (25mg/ml) 또는 증류수를 담아 섭취하도록 하고, 24시간 간격으로 도살하여 위궤양 지수를 측정하였다.Ethanol was orally administered to the rats to induce stomach ulcers. Then, 1.5 hours after the ethanol administration, the rats were slaughtered at intervals of 24 hours in a bucket containing the suspension of the glutinous rice extract-precipitated fraction (25 mg / ml) or distilled water prepared in Example 2, Respectively.
그 결과 제11도에 나타낸 바와 같이 찹쌀추출액침전분획 섭취군은 증류수 섭취 대조군에 비하여 위궤양 치유속도가 현저히 빨랐다.As a result, as shown in Fig. 11, the rate of gastric ulcer healing was significantly faster than that of the distilled water-fed control group in the glutinous rice extract-precipitated fraction-fed group.
2)DDC 유발 위궤양에 대한 찹쌀추출액침전분획의 항궤양작용 확인2) Confirming the anti-ulcerative activity of DDT-induced gastric ulcer by precipitation fraction of glutinous rice extract
제조실시예 2의 찹쌀추출액침전분획을 25mg/ml 농도로 증류수에 부유시켜 이를 흰쥐에게 3일 동안 섭취시킨 후에 DDC를 동물 체중 1kg 당 800mg 씩 피하주사하고 12시간 후에 도살하여 위궤양지수를 측정하였다.The precipitated fraction of the glutinous rice extract of Example 2 was suspended in distilled water at a concentration of 25 mg / ml, and it was taken in rats for 3 days. DDC was injected subcutaneously 800 mg per 1 kg of animal body weight and slaughtered after 12 hours to measure the gastric ulcer index.
그 결과 제12도에서 볼 수 있듯이 찹쌀추출액침전분획 섭취군의 평균 위궤양지수는 1.6로 증류수를 섭취시킨 대조군의 평균 위궤양지수 12.6에 비해 현저히 낮았다. 이로써 찹쌀추출액침전분획이 DDC 유발 위궤양도 크게 방어함을 알 수 있다.As a result, as shown in Fig. 12, the mean gastric ulcer index in the group of ingested glutinous rice extract solution fraction was 1.6 The mean gastric ulcer index of the control group receiving distilled water was 12.6 Respectively. This suggests that the precipitation fraction of glutinous rice extract significantly inhibits DDC induced gastric ulcer.
[실험예 4][Experimental Example 4]
(찹쌀추출물의 안정성)(Stability of glutinous rice extract)
제조실시예 1의 찹쌀 추출액을 십이지장궤양 환자 (8인)에게 250ml 씩 1일 3회, 2-11주 복용시킨 경우에도 어떠한 부작용이 보이지 않았으며, 제조실시예 2의 찹쌀추출액침전분획을 정상인 지원자 5인에게 5g 씩 1일 3회, 10주간 복용시키더라도 부작용이 전혀 관찰되지 않았다.No side effects were observed when 250 ml of the glutinous rice extract of Preparation Example 1 was administered to the duodenal ulcer patient (8 persons) three times a day for 2 to 11 weeks, and the glutinous rice extract precipitate fraction of Preparation Example 2 was administered to normal volunteers No side effects were observed when 5 g was given to 5 persons three times a day for 10 weeks.
[제제실시예 1][Formulation Example 1]
(정제)(refine)
찹쌀 25g을 증류수 50-75ml로 추출한 찹쌀추출액을 냉동건조시켜 얻은 약 500mg의 고형분말을 주성분으로 함유하는 정제를 통상의 정제화 과정에 따라 수득하였다.A tablet containing about 500 mg of the solid content as a major component obtained by freeze-drying a glutinous rice extract obtained by extracting 25 g of glutinous rice with 50 to 75 ml of distilled water was obtained according to a conventional tableting process.
찹쌀추출물 고형분말 500 mgGlutinous rice extract solids 500 mg
엽산 0.5 mgFolic acid 0.5 mg
전분 500 mgStarch 500 mg
[제제실시예 2][Formulation Example 2]
(캡슐)(capsule)
하기의 성분을 잘 혼합한 다음, 그 혼합물을 체질 하여 경질 젤라틴 캡슐에 충전하여 500mg의 찹쌀추출물 고형제제를 함유하는 캡슐을 수득하였다. 이때 찹쌀추출물 고형분말은 제제실시예 4 에서와 같은 방법으로 제조하였다..The following ingredients were mixed well and the mixture was sieved and filled into hard gelatine capsules to obtain capsules containing 500 mg of glutinous rice extract solid preparation. At this time, the solid content of the glutinous rice extract was prepared in the same manner as in Preparation Example 4.
찹쌀추출물 고형분말 500 mgGlutinous rice extract solids 500 mg
전분 280 mgStarch 280 mg
유당 280 mgLactose 280 mg
Claims (3)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019960047695A KR100208969B1 (en) | 1995-10-26 | 1996-10-23 | Anti-ulcers drug containing extract from chap-rice |
| KR1019990001583A KR100253740B1 (en) | 1996-10-23 | 1999-01-20 | A beverage for prevention of ulcer comprising glutinous rice extracts |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR19950037338 | 1995-10-26 | ||
| KR101995037338 | 1995-10-26 | ||
| KR1019960047695A KR100208969B1 (en) | 1995-10-26 | 1996-10-23 | Anti-ulcers drug containing extract from chap-rice |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR970020114A KR970020114A (en) | 1997-05-28 |
| KR100208969B1 true KR100208969B1 (en) | 1999-07-15 |
Family
ID=66314897
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1019960047695A KR100208969B1 (en) | 1995-10-26 | 1996-10-23 | Anti-ulcers drug containing extract from chap-rice |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100208969B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013162126A1 (en) * | 2012-04-24 | 2013-10-31 | Dasan M&F, Inc. | Anti-inflammatory composition for the intestine comprising glutinous rice water-extracts |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010104425A (en) * | 2000-04-27 | 2001-11-26 | 안봉환 | Composition with anti-ulcer activity comprising extracts of glutinous rice and raw ginseng |
| KR100821943B1 (en) * | 2007-03-27 | 2008-04-15 | 다산엠앤에프(주) | Clear liquid anti-ulcer preparations made of glutinous rice and tea extracts |
| CN116920049B (en) * | 2023-07-12 | 2024-05-31 | 中南民族大学 | Skin-care oil for treating gastric ulcer and preparation method and application thereof |
-
1996
- 1996-10-23 KR KR1019960047695A patent/KR100208969B1/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013162126A1 (en) * | 2012-04-24 | 2013-10-31 | Dasan M&F, Inc. | Anti-inflammatory composition for the intestine comprising glutinous rice water-extracts |
Also Published As
| Publication number | Publication date |
|---|---|
| KR970020114A (en) | 1997-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rasyid et al. | The effect of curcumin and placebo on human gall‐bladder function: an ultrasound study | |
| KR960016582B1 (en) | Pharmaceutical compositions for treating and preventing gastrointestinal disorders | |
| Skidmore-Roth | Mosby's handbook of herbs & natural supplements | |
| Boyd et al. | Smoking impairs therapeutic gastric inhibition | |
| US6811796B2 (en) | Preventive or therapeutic agent for pollen allergy, allergic rhinitis, atopic dermatitis, asthma or urticaria, or health food for prevention or improvement or reduction of symptoms thereof | |
| US5989588A (en) | Methods and compositions for preventing and treating heartburn | |
| EP0405930A2 (en) | Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives | |
| US6217880B1 (en) | Medicament for treating recurrent ulcer of mouth and behcet's syndrome | |
| US5837254A (en) | Method of treating candida and cryptococcus fungal infections by administering gentian | |
| US4642232A (en) | Formulated allergen preparation and its use | |
| KR100208969B1 (en) | Anti-ulcers drug containing extract from chap-rice | |
| EP0190851B1 (en) | Improved antiinflammatory composition | |
| KR100500373B1 (en) | Composition for hangover cures | |
| JP2020525407A (en) | Methods and compositions for treating congenital diarrhea disorders | |
| KR100627820B1 (en) | A herbal preparation with anti-ulcer activity composed of glutinous rice and tea extracts | |
| Gupta et al. | Evaluation of anti-ulcer effect of root of Curcuma zedoaria in rats | |
| US20020119183A1 (en) | Mineral supplement | |
| CZ79593A3 (en) | Antitussive preparation | |
| Borysiewicz et al. | Scombrotoxic atrial flutter. | |
| JP4786166B2 (en) | Antacid composition | |
| US20030059485A1 (en) | Treatment of allergic rhinitis | |
| KR20010104425A (en) | Composition with anti-ulcer activity comprising extracts of glutinous rice and raw ginseng | |
| Street | The Composition of Certain Patent and Proprietary Medicines | |
| KR100821943B1 (en) | Clear liquid anti-ulcer preparations made of glutinous rice and tea extracts | |
| Porro et al. | Antacids for duodenal ulcer: current role |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| A107 | Divisional application of patent | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130418 Year of fee payment: 15 |
|
| FPAY | Annual fee payment |
Payment date: 20140419 Year of fee payment: 16 |
|
| FPAY | Annual fee payment |
Payment date: 20150918 Year of fee payment: 17 |
|
| FPAY | Annual fee payment |
Payment date: 20160426 Year of fee payment: 18 |
|
| EXPY | Expiration of term |